A new study from South Africa:
Pfizer Inc.’s vaccine provides less immunity to the omicron variant than to other major versions of Covid-19, according to laboratory experiments that indicate a booster may still help stop the highly mutated strain.
Researchers at the Africa Health Research Institute in Durban, South Africa found omicron reduces virus-blocking antibodies by 40-fold in people who have received two doses of the Pfizer-BioNTech SE shot, compared with the strain detected in China almost two years ago.